Company intelligence / Profile preview

Jiangsu Maidu Pharmaceutical Research and Development

Ownership: Private
Employees: ~900
Development stage: Other

Overview

Jiangsu Maidu Pharmaceutical Research and Development, a subsidiary of Zelgen, is primarily focused on developing small molecule oncology therapies. Its lead program, sutetinib maleate, has demonstrated clinical activity in Phase 2 trials for non-small cell lung cancer patients with rare EGFR mutations. Its dual BTK/EGFR inhibitor, kenaitinib, is currently in Phase 1 clinical testing for B-cell lymphomas.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

kenaiteinib

Partnerships

Gensun BiopharmaAlphamab Oncology

Beyond the preview

Go deeper on Jiangsu Maidu Pharmaceutical Research and Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Maidu Pharmaceutical Research and Development.